Through this collaboration, Molbio will promote and distribute Thermalytix in both public and private healthcare markets globally
Molbio Diagnostics has announced the launch of a strong collaboration with Niramai Health Analytix, a Bangalore-based deep-tech startup. This partnership aims to accelerate the adoption of Niramai’s innovative AI-based non-invasive breast cancer screening solution, Thermalytix in developing countries around the world.
Thermalytix uses thermal scanning coupled with smart automated AI-enabled software that is able to detect early signs of breast cancer which otherwise would not have been detected through traditional methods. It enables non- touch screening and is aligned with privacy needs of patients, thereby overcoming hesitation for breast examination. Additionally, this imaging method is radiation free, pain less and suitable to all age groups, even young women with dense breasts.
Through this collaboration, Molbio will promote and distribute Thermalytix in both public and private healthcare markets globally. The partnership builds on the strengths of the two companies to bring cutting-edge technology which would make high-quality diagnostics accessible to everyone.
Commenting on the collaboration, Sriram Natarajan, Vice President – Sales & Marketing of Molbio commented, “We are thrilled to add another cap to our universal access portfolio of innovative healthcare solutions. Niramai’s AI-based Thermalytix device for breast cancer and Molbio’s Truenat HPV-HR test for cervical cancer will enable point of care screening and early detection of the two most deadly cancers of women worldwide, saving millions of lives.”
Highlighting the benefit of the collaboration Dr Geetha Manjunath, Founder and CEO, Niramai Health Analytix said, “We are very excited to announce this partnership which has the potential to take our affordable and automated breast screening test to every lady, world over and improve health equity.”
- Advertisement -